Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans. / van Son, Jamie; Serlie, Mireille J.; Stahlman, Marcus; Backhed, Fredrik; Nieuwdorp, Max; Aron-Wisnewsky, Judith.

In: Nutrients, Vol. 13, No. 8, 2706, 2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

van Son, J, Serlie, MJ, Stahlman, M, Backhed, F, Nieuwdorp, M & Aron-Wisnewsky, J 2021, 'Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans', Nutrients, vol. 13, no. 8, 2706. https://doi.org/10.3390/nu13082706

APA

van Son, J., Serlie, M. J., Stahlman, M., Backhed, F., Nieuwdorp, M., & Aron-Wisnewsky, J. (2021). Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans. Nutrients, 13(8), [2706]. https://doi.org/10.3390/nu13082706

Vancouver

van Son J, Serlie MJ, Stahlman M, Backhed F, Nieuwdorp M, Aron-Wisnewsky J. Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans. Nutrients. 2021;13(8). 2706. https://doi.org/10.3390/nu13082706

Author

van Son, Jamie ; Serlie, Mireille J. ; Stahlman, Marcus ; Backhed, Fredrik ; Nieuwdorp, Max ; Aron-Wisnewsky, Judith. / Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans. In: Nutrients. 2021 ; Vol. 13, No. 8.

Bibtex

@article{6145593fb40945c68a67831633a799c8,
title = "Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans",
abstract = "Background: The gut microbiota and its metabolites are essential for host health and dysbiosis has been involved in several pathologic conditions such as type 2 diabetes (T2D) and cardiovascular disease (CVD). Recent studies have identified that plasma imidazole propionate (ImP), a microbial-produced metabolite, is increased in patients with prediabetes and T2D. More recently, ImP was found to be significantly increased in patients with overt CVD. Here, we aimed to investigate the association between ImP and CVD risk factors: blood pressure, HDL-cholesterol, LDL-cholesterol and insulin-resistance in overweight and obese subjects without T2D or use of any metabolic diseases-related medication. Methods: Plasma metabolites, including ImP, were determined in 107 male or post-menopausal women with overweight/obesity, but without T2D. Insulin-sensitivity was assessed with the gold standard method: the hyperinsulinemic-euglycemic clamp using the isotope [6,6-H-2(2)] glucose and expressed as glucose rate of disposal (Rd) for peripheral insulin sensitivity and suppression of endogenous glucose production (EGP) for hepatic insulin sensitivity. Results: Partial correlation analysis controlled for BMI and age showed a significant correlation between ImP and diastolic blood pressure (r(s) = 0.285, p = 0.004) and a borderline significance with systolic blood pressure (r(s) = 0.187, p = 0.060); however, systolic and diastolic blood pressure did not correlate with ImP precursor histidine (r(s) = 0.063, p = 0.526 and r = -0.038, p = 0.712, respectively). We did not find a correlation between ImP with LDL-cholesterol or HDL-cholesterol (r(s) = -0.181, p = 0.064 and r(s) = 0.060, p = 0.546, respectively). Furthermore, there was no association between plasma ImP concentrations and Rd and EGP suppression. Conclusion: In this cohort with overweight/obese subjects without T2D, plasma ImP concentrations were positively correlated with diastolic blood pressure but not with insulin-sensitivity.",
keywords = "imidazole propionate, cardiovascular disease, insulin resistance, obesity, gut microbiota, hyperinsulinemic-euglycemic clamp, INSULIN-RESISTANCE, METABOLIC SYNDROME, DIABETES-MELLITUS, RISK-FACTORS, HYPERTENSION, GLUCOSE, SENSITIVITY, MICROBIOTA, INSIGHTS, DISEASE",
author = "{van Son}, Jamie and Serlie, {Mireille J.} and Marcus Stahlman and Fredrik Backhed and Max Nieuwdorp and Judith Aron-Wisnewsky",
year = "2021",
doi = "10.3390/nu13082706",
language = "English",
volume = "13",
journal = "Nutrients",
issn = "2072-6643",
publisher = "M D P I AG",
number = "8",

}

RIS

TY - JOUR

T1 - Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans

AU - van Son, Jamie

AU - Serlie, Mireille J.

AU - Stahlman, Marcus

AU - Backhed, Fredrik

AU - Nieuwdorp, Max

AU - Aron-Wisnewsky, Judith

PY - 2021

Y1 - 2021

N2 - Background: The gut microbiota and its metabolites are essential for host health and dysbiosis has been involved in several pathologic conditions such as type 2 diabetes (T2D) and cardiovascular disease (CVD). Recent studies have identified that plasma imidazole propionate (ImP), a microbial-produced metabolite, is increased in patients with prediabetes and T2D. More recently, ImP was found to be significantly increased in patients with overt CVD. Here, we aimed to investigate the association between ImP and CVD risk factors: blood pressure, HDL-cholesterol, LDL-cholesterol and insulin-resistance in overweight and obese subjects without T2D or use of any metabolic diseases-related medication. Methods: Plasma metabolites, including ImP, were determined in 107 male or post-menopausal women with overweight/obesity, but without T2D. Insulin-sensitivity was assessed with the gold standard method: the hyperinsulinemic-euglycemic clamp using the isotope [6,6-H-2(2)] glucose and expressed as glucose rate of disposal (Rd) for peripheral insulin sensitivity and suppression of endogenous glucose production (EGP) for hepatic insulin sensitivity. Results: Partial correlation analysis controlled for BMI and age showed a significant correlation between ImP and diastolic blood pressure (r(s) = 0.285, p = 0.004) and a borderline significance with systolic blood pressure (r(s) = 0.187, p = 0.060); however, systolic and diastolic blood pressure did not correlate with ImP precursor histidine (r(s) = 0.063, p = 0.526 and r = -0.038, p = 0.712, respectively). We did not find a correlation between ImP with LDL-cholesterol or HDL-cholesterol (r(s) = -0.181, p = 0.064 and r(s) = 0.060, p = 0.546, respectively). Furthermore, there was no association between plasma ImP concentrations and Rd and EGP suppression. Conclusion: In this cohort with overweight/obese subjects without T2D, plasma ImP concentrations were positively correlated with diastolic blood pressure but not with insulin-sensitivity.

AB - Background: The gut microbiota and its metabolites are essential for host health and dysbiosis has been involved in several pathologic conditions such as type 2 diabetes (T2D) and cardiovascular disease (CVD). Recent studies have identified that plasma imidazole propionate (ImP), a microbial-produced metabolite, is increased in patients with prediabetes and T2D. More recently, ImP was found to be significantly increased in patients with overt CVD. Here, we aimed to investigate the association between ImP and CVD risk factors: blood pressure, HDL-cholesterol, LDL-cholesterol and insulin-resistance in overweight and obese subjects without T2D or use of any metabolic diseases-related medication. Methods: Plasma metabolites, including ImP, were determined in 107 male or post-menopausal women with overweight/obesity, but without T2D. Insulin-sensitivity was assessed with the gold standard method: the hyperinsulinemic-euglycemic clamp using the isotope [6,6-H-2(2)] glucose and expressed as glucose rate of disposal (Rd) for peripheral insulin sensitivity and suppression of endogenous glucose production (EGP) for hepatic insulin sensitivity. Results: Partial correlation analysis controlled for BMI and age showed a significant correlation between ImP and diastolic blood pressure (r(s) = 0.285, p = 0.004) and a borderline significance with systolic blood pressure (r(s) = 0.187, p = 0.060); however, systolic and diastolic blood pressure did not correlate with ImP precursor histidine (r(s) = 0.063, p = 0.526 and r = -0.038, p = 0.712, respectively). We did not find a correlation between ImP with LDL-cholesterol or HDL-cholesterol (r(s) = -0.181, p = 0.064 and r(s) = 0.060, p = 0.546, respectively). Furthermore, there was no association between plasma ImP concentrations and Rd and EGP suppression. Conclusion: In this cohort with overweight/obese subjects without T2D, plasma ImP concentrations were positively correlated with diastolic blood pressure but not with insulin-sensitivity.

KW - imidazole propionate

KW - cardiovascular disease

KW - insulin resistance

KW - obesity

KW - gut microbiota

KW - hyperinsulinemic-euglycemic clamp

KW - INSULIN-RESISTANCE

KW - METABOLIC SYNDROME

KW - DIABETES-MELLITUS

KW - RISK-FACTORS

KW - HYPERTENSION

KW - GLUCOSE

KW - SENSITIVITY

KW - MICROBIOTA

KW - INSIGHTS

KW - DISEASE

U2 - 10.3390/nu13082706

DO - 10.3390/nu13082706

M3 - Journal article

C2 - 34444866

VL - 13

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 8

M1 - 2706

ER -

ID: 279259187